Misplaced Pages

KL-50

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (June 2024)
KL-50
Identifiers
CAS Number
3D model (JSmol)
InChI
  • InChI=1S/C7H7FN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15)Key: RXJOSBAVDXNQEY-UHFFFAOYSA-N
SMILES
  • FCCN1N=NC2=C(C(=O)N)N=CN2C(=O)1
Properties
Chemical formula C7H7FN6O2
Molar mass 226.171 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references
Chemical compound

KL-50 (also known as RR-004 by its developer Pharminox Limited) is a drug candidate designed to treat glioblastoma. It functions by alkylating DNA yielding O6-(2-fluoroethyl)guanine which causes DNA interstrand crosslinks. Half of the cancers are unable to repair the DNA damage.

The KL-50 molecule was patented by Pharminox Limited in 2013, detailing its potential use in treating MMR-/MGMT- gliomas.

References

  1. Huseman, Eric; Lo, Anna; Fedorova, Olga; Elia, James; Gueble, Susan; Lin, Kingson; Sundaram, Ranjini; Burgenske, Danielle; Oh, Joonseok; Liu, Jinchan; Menges, Fabian; Rees, Matthew; Ronan, Melissa; Roth, Jennifer; Batista, Victor; Crawford, Jason; Sarkaria, Jann; Pyle, Anna; Bindra, Ranjit; Herzon, Seth (2023). "Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers". ChemRxiv. doi:10.26434/chemrxiv-2023-zwj94.
  2. Huseman, Eric D.; Lo, Anna; Fedorova, Olga; Elia, James L.; Gueble, Susan E.; Lin, Kingson; Sundaram, Ranjini K.; Oh, Joonseok; Liu, Jinchan; Menges, Fabian; Rees, Matthew G.; Ronan, Melissa M.; Roth, Jennifer A.; Batista, Victor S.; Crawford, Jason M.; Pyle, Anna M.; Bindra, Ranjit S.; Herzon, Seth B. (30 May 2024). "Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers". Journal of the American Chemical Society. 146 (27): 18241–18252. doi:10.1021/jacs.3c06483. PMC 11409917. PMID 38815248.
  3. "Slow and steady action makes brain cancer drug candidate more selective". Chemical & Engineering News.
  4. Leslie, Mitch (2 November 2022). "New Strategy May Thwart Glioblastoma Resistance". Cancer Discovery. 12 (11): 2488–2489. doi:10.1158/2159-8290.CD-NB2022-0055.
  5. US application 2013338104 
Categories: